Slide 1: Conference Call | Financial Results 2022
Conference Call | Financial Results 2022 Gregor Siebert, CEO | Sebastian Werner, CFO 30 March 2023
Slide 2: Disclaimer
Disclaimer It is important to note that this information contains forward-looking statements which are based on the currently held beliefs and assumptions of the management of PAION AG, which are expressed in good faith and, in its opinion, reasonable. Forward-looking statements involve known and un
Slide 3: Agenda
AGENDA 1 Corporate Overview 2 Products 3 Financials 3 | www.paion.com
Slide 4: PAION Mission Statement
PAION Mission Statement “ “ PAION’s mission is to be a leading specialty pharmaceutical company in the fields of anaesthesia & critical care by bringing novel products to market to benefit patients, doctors & other stakeholders in healthcare. 4 | www.paion.com
Slide 5: PAION strategy
PAION strategy Continue to explore synergistic Establishment of a professional opportunities and in-licensing to commercial organization in Europe drive longer term growth Target: Innovative Leader in Continue to launch remimazolam Anaesthesia & Critical Care (brand name Byfavo®), angiotensin II (br
Slide 6: PAION AG at a glance
PAION AG at a glance PAION AG is a specialty pharmaceutical company Approval for remimazolam in all major pharmaceutical markets, focusing on anesthesia and critical care products Market launch in Europe, Japan, South Korea, Taiwan and the USA, plus licensing in Latin America and Southeast Asia. 3 i
Slide 7: Gregor Siebert appointed as CEO
Gregor Siebert appointed as CEO with more than 30 years of pharma & medical device industry experience Global Sales & Marketing Executive with proven track record of restructuring, building and driving sales organizations Key Expertise: Europe and Emerging Markets, Sales & Marketing Strategy and Exe
Slide 8: Sebastian Werner appointed as CFO
Sebastian Werner appointed as CFO with more than 20 years of pharma experience Finance Executive with proven track record in the pharma industry Key Expertise: Extensive experience in finance. Senior positions in the pharmaceutical and life science industry for over 20 years. He started this interna
Slide 9: Important events 2022/23
Important events 2022/23 Establishment of sales and thus intensified activities in the target markets Humanwell buys China patents for € 20.5m Cristália partnership for Latin America expands commercial availability of remimazolam New distribution partner: Acquisition of US partner Acacia by Eagle Ph
Slide 10: Targets for PAION 2023
Targets for PAION 2023 Market approval remimazolam EU and UK General Anaesthesia(H1 2023) Further launches of remimazolam, angiotensin II and eravacycline Market Access of remimazolam, angiotensin II and eravacycline in EU Core Markets Growth in remimazolam sales through partners and launch activiti
Slide 11: Agenda
AGENDA 1 Corporate Overview 2 Products 3 Financials 11 | www.paion.com
Slide 12: Pipeline
Pipeline 2021 '22 '23 '24 '25 '26 '27 '28 '29 '30 '31 '32 '33 '34 '35 '36 Adults 12y - 18y Procedural sedation 2y – 12y 0y – 2y March '36 Adults TCI General anesthesia 2y - 18y Adults Distributive shock Dec '34 2y - 18y Adults Complicated intra-abdominal Sep '33 2y - 18y infections Year of first lau
Slide 13: Three innovative products for acute care in Europe
Three innovative products for acute care in Europe Angiotensin II Remimazolam Eravacycline Indication: septic or other distributive shock*. Indication: procedural sedation for adults. Indication: treatment of complicated intra- abdominal infections (cIAI) in adults**. Leverages a system (RAAS) tha
Slide 14: Remimazolam (Byfavo®)
Remimazolam (Byfavo®) 14 | www.paion.com
Slide 15: The ideal drug would combine the best of both worlds
The ideal drug would combine “the best of both worlds”* Propofol Remimazolam Midazolam CV/Respiratory Rapid onset/offset Lower safety issues Variable and depression Predictable Reversal agent prolonged periods No reversal agent recovery time of sedation Less resources Pain on injec
Slide 16: Remimazolam launched worldwide – licensing and supply to regional experts
Remimazolam launched worldwide – licensing and supply of acute and specialty pharmaceuticals to regional experts Hana Pharm S. Korea launch 2021 Mundipharma Eagle Pharmaceutical Japan launch 2020 USA launch 2021 Yichang Humanwell China launch 2020 (IP sold to Humanwell in 2022) Cristália Brazil TTY
Slide 17: PAION's partners
PAION's partners U.S. - Eagle Pharma Japan - Mundipharma Taiwan - TTY BIOPHARM Lead indication: procedural sedation Lead indication: general anesthesia License agreement signed in 2021 BYFAVOTM launched in 2021 Mundipharma launched Anerem® in 2020 Approval received 2022 Royalties 20-25
Slide 18: Target groups: Physicians
Target groups: Physicians The sedation experts: anaesthesiologists Safety oriented & specialist skillset Key person for the introduction of a new sedation drug, Decision-makers in favor of promoting remimazolam, very positive toward remimazolam. The experts for interventions: gastroenterologis
Slide 19: Other key stakeholders
Other key stakeholders Specialized personnel Hospital Pharmacist High-Level Payers Important part of the multidisciplinary Key decision makers for the Collaboration on market access team inclusion of remimazolam in the and reimbursement Responsible for the preparation and drug lists Comple
Slide 20: General anesthesia - target market IV market and critically ill patients
General anesthesia - target market IV market and critically ill patients IV MARKET PATIENT FOCUS Concentration on the IV market Focus on ASA III and IV patients. Concentration on the IV market Phase III studies conducted Switching strategy from IV anesthetics (e.g., propofol) to remimazola
Slide 21: Strong overlap in accounts and target groups
Strong overlap in accounts and target groups ICU/Theatre/ Intensivist/ Anesthetist/ Surgeon Theatre/ED/ ICU/Theatre Procedures/ /ED/Gastro- Anesthetist / surgeon/ Gastroente- Intensivist* rologists * Other specialties key for formulary listing, eg Inectious disease, Hospital antimicrobial stewardshi
Slide 22: PAION hosted a sponsored angiotensin II symposium at ISICEM in Brussels
PAION hosted a sponsored angiotensin II symposium at ISICEM in Brussels 22 | www.paion.com
Slide 23: Agenda
AGENDA 1 Corporate Overview 2 Products 3 Financials 23 | www.paion.com
Slide 24: Cash position and financing
Cash position and financing Cash of € 10.6m (as of 31 December 2022) PAION expects increasing revenues from licensing Patent transfer agreement (January 2022) with Humanwell for agreements and own commercialization in the coming € 20.5m years Licensing agreement with Cristália for Latin America Fina
Slide 25: Consolidated statement of comprehensive income
Consolidated statement of comprehensive income In accordance with IFRS (unaudited figures in EUR k) Revenues R&D Expenses 33,248 FY 2021 FY 2022 7,128 -5,249 -6,485 FY 2021 FY 2022 SG&A Expenses Net Result FY 2021 FY 2022 FY 2021 FY 2022 -579 -19,828 -21,198 -21,786 Revenues and Net Result mainly
Slide 26: Consolidated balance sheet and employees
Consolidated balance sheet and employees In accordance with IFRS (unaudited figures in EUR k, if not otherwise noted) Total assets Cash and cash equivalents 10,629 4,189 38,177 6,440 36,785 31 Dec. 2021 31 Dec. 2022 31 Dec. 2021 Total Cash Flow 31 Dec. 2022 Equity Employees (avg.) in the Group 6,999
Slide 27: Financial Outlook 2023
Financial Outlook 2023 Revenues Low: 14 Mio. €; High: 19 Mio. € EBIT Low: -15 Mio. €; High: -10,5 Mio. € 27 | www.paion.com
Slide 28: Suitable Financing Concept progressing
Suitable Financing Concept progressing Extraordinary General Meeting 2023 in January approved the proposed capital reductions by redemption and consolidation of shares. EGM Resolutions were entered into the commercial register at the local court of Aachen on 14 March 2023. With regard to the option
Slide 29: Contact
Contact: PAION AG Heussstraße 25 Phone: +49 241 44 53-0 52078 Aachen – info@paion.com Germany www.paion.com 29 | www.paion.com